Interpreting measurements of physical function in clinical trials

Annals of the Rheumatic Diseases

Volumn 66, Issue SUPPL. 3, 2007, Pages

  Ward, Michael M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; HUMANS; SELF CONCEPT; TREATMENT OUTCOME;

EID: 35648956297     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.079806     Document Type: Conference Paper

References (17)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
2. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994;41:86-9.
3. van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945-7.
4. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
5. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core set of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003;42:1452-9.
6. Bellamy N, Kirwan J, Altman R, Boers M, Brandt K, Brooks P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799-802.
7. Stucki G, Cieza A, Geyh S, Battistella L, Lloyd J, Symmons D, et al. ICF core sets for rheumatoid arthritis. J Rehabil Med 2004;44(Suppl):87-93.
8. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
9. van Leeuwen MA, van der Heidje DM, van Rijwijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
10. Welsing PM, van Gestel AM, Swikels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
11. Escalante A, del Rincón I. The disablement process in rheumatoid arthritis. Arthritis Rheum 2002;47:333-42.
12. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis. Identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
13. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
14. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
15. Aletaha D, Strand V, Smolen J, Ward MM. Treatment-related improvement in physical function varies with the duration of rheumatoid arthritis. A pooled analysis of clinical trial results. Ann Rheum Dis. Published Online First: 20 July 2007. doi: 10.1136/ard.2007.071415.
16. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70.
17. Ward MM, Marx AS, Barry NN. Identification of clinically important changes in health status using receiver operating characteristic curves. J Clin Epidemiol 2000;53:279-84.